Mark N. Tompkins - 01 Nov 2024 Form 4 Insider Report for Lomond Therapeutics Holdings, Inc.

Reporting relationship: Former Director
Issuer ticker: N/A
Reported as of: 01 Nov 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Nov 2024, 18:35:40 UTC
Prior SEC filing: 02 Aug 2023
Next SEC filing: 31 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Mark N. Tompkins

Key filing fact

Mark N. Tompkins filed Form 4 for Lomond Therapeutics Holdings, Inc. on 05 Nov 2024.

Key facts

This page summarizes Mark N. Tompkins's Form 4 filing for Lomond Therapeutics Holdings, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Nov 2024, 18:35.

Change

Previous filing in this sequence was filed on 02 Aug 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker transaction

Common Stock

Other

Transaction value: $0
Shares: -3,550,000
Change %: -75%
Price: $0.000000
Shares after: 1,200,000
Date: 01 Nov 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Mark N. Tompkins is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

As a condition under the terms of an Agreement and Plan of Merger and Reorganization, dated as of November 1, 2024, and pursuant to the terms of a stock cancellation agreement, the reporting person voluntarily surrendered and cancelled for no consideration 3,550,000 shares of Issuer's common stock prior to the consummation of the Merger on November 1, 2024. The reporting person resigned as a director of the Issuer upon consummation of the Merger.